Effects of sodium-glucose transporter-2 inhibition on systemic hemodynamics, renal function, and intra-renal oxygenation in sepsis-associated acute kidney injury

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Effects of sodium-glucose transporter-2 inhibition on systemic hemodynamics, renal function, and intra-renal oxygenation in sepsis-associated acute kidney injury
Συγγραφείς: Abraham H. Hulst, Connie P. C. Ow, Clive N. May, Sally H. Hood, Mark P. Plummer, Jeroen Hermanides, Daniël H. van Raalte, Adam M. Deane, Rinaldo Bellomo, Yugeesh R. Lankadeva
Πηγή: Intensive Care Medicine Experimental, Vol 12, Iss 1, Pp 1-10 (2024)
Στοιχεία εκδότη: SpringerOpen, 2024.
Έτος έκδοσης: 2024
Συλλογή: LCC:Medical emergencies. Critical care. Intensive care. First aid
Θεματικοί όροι: Sodium-glucose transporter 2 inhibitor, Empagliflozin, Sepsis, Acute kidney injury, Medullary oxygenation, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Περιγραφή: Abstract Background People with type 2 diabetes mellitus treated with sodium-glucose transporter-2 inhibitors (SGLT2i) have lower rates of acute kidney injury (AKI). Sepsis is responsible for the majority of AKI in critically ill patients. This study investigated whether SGLT2i is renoprotective in an ovine model of Gram-negative septic AKI. Methods Sixteen healthy merino ewes were surgically instrumented to enable measurement of mean arterial pressure, cardiac output, renal blood flow, renal cortical and medullary perfusion, and oxygenation. After a 5-day recovery period, sepsis was induced via slow and continuous intravenous infusion of live Escherichia coli. Twenty-three hours later, sheep were randomized to receive an intravenous bolus of 0.2 mg/kg empagliflozin (n = 8) or a fluid-matched vehicle (n = 8). Results Empagliflozin treatment did not significantly reduce renal medullary hypoperfusion or hypoxia, improve kidney function, or induce histological changes. Renal cortical oxygenation during the intervention period was 47.6 ± 5.9 mmHg in the empagliflozin group compared with 40.6 ± 8.2 mmHg in the placebo group (P = 0.16). Renal medullary oxygenation was 28.0 ± 18.5 mmHg in the empagliflozin compared with 25.7 ± 16.3 mmHg (P = 0.82). Empagliflozin treatment did not result in significant between-group differences in renal blood flow, kidney function, or renal histopathological changes. Conclusion In a large mammalian model of septic AKI, a single dose of empagliflozin did not improve renal microcirculatory perfusion, oxygenation, kidney function, or histopathology.
Τύπος εγγράφου: article
Περιγραφή αρχείου: electronic resource
Γλώσσα: English
ISSN: 2197-425X
Relation: https://doaj.org/toc/2197-425X
DOI: 10.1186/s40635-024-00647-2
Σύνδεσμος πρόσβασης: https://doaj.org/article/fb3379f34b1d4f398e64131e44166cb9
Αριθμός Καταχώρησης: edsdoj.fb3379f34b1d4f398e64131e44166cb9
Βάση Δεδομένων: Directory of Open Access Journals
Περιγραφή
ISSN:2197425X
DOI:10.1186/s40635-024-00647-2